DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/k7wmzb/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" report to their offering.
Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Glioblastoma Multiforme (GBM) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Glioblastoma Multiforme (GBM).
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
-
Listings of discontinued trials (suspended, withdrawn and terminated)
Clinical Trial Overview of Top Companies/Institutions
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.
- AstraZeneca PLC
- Eli Lilly and Company
- Eisai Co., Ltd.
- Medicenna Therapeutics, Inc
- E. Merck KG
- Bristol-Myers Squibb Company
- National Cancer Institute
- The University of Texas M. D. Anderson Cancer Center
- Duke University
- Massachusetts General Hospital
- European Organization for Research and Treatment of Cancer
- Rigshospitalet
- Cedars-Sinai Medical Center
- Case Comprehensive Cancer Center
- University of Zurich
For more information visit http://www.researchandmarkets.com/research/k7wmzb/recurrent
